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Acute graft-versus-host disease (aGVHD) is the major cause of morbidity and mortality after allogeneic he-
matopoietic stem cell transplantation. Systemic steroid treatment represents the ﬁrst-line therapy for aGVHD
and is associated with a response rate of 30% to 60%. Steroid-resistant patients have a poor prognosis with
high transplantation-related mortality (TRM). Several second-line therapies have been proposed for the
management of unresponsive aGVHD, without proven beneﬁcial effects on patients’ outcome or overall long-
term survival. For these reasons, extracorporeal photochemotherapy/photopheresis (ECP), a cell-based
approach to control GVHD that spares generalized immunosuppression, seems to be promising. In this
study, we report the outcome of 72 consecutive pediatric patients treated with ECP between 1997 and 2013
for aGVHD. Among them, 21 patients had steroid-resistant aGVHD, 42 had steroid-dependent aGVHD, and 9
did not receive steroid as ﬁrst-line therapy because of clinical contraindications. A complete response was
obtained in 72% of patients, a partial response was observed in 11%, and there was no response in 17% of
patients. At day þ180, TRM was 4% in the whole cohort; TRM was 3% and 20% among responders and
nonresponders to ECP, respectively (P < .0001). The 5-year overall survival was 71%, showing a difference
between responders and nonresponders of 78% and 30%, respectively (P ¼ .0004). The 5-year time to pro-
gression of primary disease was 81%, without any signiﬁcant difference between the 2 groups. Moreover, the
5-year progression-free survival of primary disease was 72%, with a signiﬁcant difference (P ¼ .0007) between
responders (79%) and nonresponders (30%) to ECP. In conclusion, this study demonstrates that ECP is highly
effective in aGVHD without a negative impact on primary disease.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic (allo) hematopoietic stem cell transplantation
(HSCT) is increasingly used as a therapeutic approach for
hematological and nonhematological diseases. In the last
decade, improvements in infection monitoring and prophy-
laxis, immunosuppressive (IS) strategies, high-resolution
HLA typing, and supportive care measures led to better
outcomes after this procedure. Despite these advancements,dgments on page 1971.
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ty for Blood and Marrow Transplantation.acute graft-versus-host disease (aGVHD) remains the major
cause of morbidity and mortality after allo-HSCT [1,2].
To standardize diagnosis and management of aGVHD, a
British guideline was published by a joint working group of
the British Committee for Standards in Haematology and the
British Society for Bone Marrow Transplantation. This
document included recommendations for diagnosis and
management of aGVHD as well as primary treatment options
for patients with steroid-refractory (SR) disease [3].
Standard management of aGVHD included steroids at
different doses depending on aGVHD grade. If no improve-
ment of aGVHD after 7 days was noted or progressionwithin
72 hours were observed, then the addition of second-
line agents should be considered. Second-line options are
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mammalian target of rapamycin inhibitors, IL-2 receptor
antibodies, and extracorporeal photochemotherapy/photo-
pheresis (ECP) [3].
Unfortunately, despite multiple clinical trials, no single
agent improving overall survival (OS) for patients who failed
steroid treatment has been identiﬁed [4,5].
Moreover, the current survival at years in patients
who respond to steroids is about 36% versus 17% in
nonresponders (NR) [6] and it has been shown that
transplantation-related mortality (TRM) is higher in steroid-
resistant patients [7,8].
In our study, we focused on ECP, one of the most prom-
ising treatments for aGVHD. Brieﬂy, ECP consists of 3 pro-
cedures: collection of peripheral leukocytes cells, irradiation
of cells by ultraviolet A light in presence of 8-
methoxypsoralen (8-MOP), and reinfusion of treated cells
in the patient. The underlying mechanism of action of ECP in
GVHD is not completely understood [9,10]. Within 24 hours,
this process induces apoptosis of all treated cells (including
T cells) and subsequent phagocytosis by antigen-presenting
cells; as a result, this might regulate immune homoeo-
stasis, modulate the cytokine production, and induce toler-
ance of antigen-presenting cells [10-13].
ECP has been demonstrated to be effective in treating
both steroid-resistant and steroid-dependent patients with
aGVHD [14-17]. In the pediatric setting in particular, the re-
ported response rate ranges from 50% to 100%, according to
the organs involved. In aGVHD steroid-resistant patients, 5-
year OS is signiﬁcantly increased in complete responders to
ECP, 69% compared with 12% for NR [18].
In 2013, the Italian Society of Haemapheresis and Cell
Manipulation and the Italian Group of Bone Marrow Trans-
plantation elaborated best practice recommendations for
ECP, which reﬂected the common clinical practice in most
Italian transplantation centers where ECP is performed with
a total of 4500 procedures per year [19]. Despite this large
use of ECP, most of the published reports deal with retro-
spective data that are difﬁcult to compare, as patients’ se-
lection criteria, treatment schedules, patients’ monitoring,
and patients’ assessment protocols differ among institutions.
Moreover, no randomized studies have been conducted in
patients with aGVHD.
Here, we report our single-center experience on ECP
treatment in 72 pediatric patients with aGVHD. The response
to ECP, TRM, OS, progression-free survival (PFS) of primary
disease, and time to progression (TTP) of primary disease of
patients treated with ECP were analyzed.MATERIAL AND METHODS
Patients
From January 1997 to June 2013, 72 consecutive pediatric patients (44
males, 28 females) affected by aGVHD were treated with ECP at the HSCT
Unit of University Hospital of Padova. Fifteen of these 72 patients have been
previously reported [20]. The clinical characteristics of patients are shown in
Table 1. The median age at ECP was 8.3 years (range, .9 to 20.3 years) and the
median bodyweight was 25 kg (range, 7 to 98 kg). Fifteen childrenweighted
less than 15 kg. The last follow-up was ﬁxed on June 2014. In detail, 21
patients were treated with ECP for aGVHD refractory to steroids, which was
deﬁned as a progression or no improvement in aGVHD after at least 3 days
or 7 days on methylprednisolone (MP)  2 mg/kg body weight, respectively
(SR group); 21 patients for steroid-dependant aGVHD, deﬁned as a ﬂare-up of
aGVHD during the tapering of MP (SD group); and 30 children with aGVHD
who required a reduction of pharmacological IS or contraindications to IS
therapy for viral reactivations, systemic mycoses, or intolerable side effects
(group with infectious complications [IC]). In particular, 9 of 30 patients in
the IC group (IC-A group) underwent ECP without steroids as a ﬁrst-line
therapy because of contraindications: 1 for TCR ab and CD19edepletedhaploidentical transplantation with probable invasive pulmonary aspergil-
losis (IPA) and adenovirus (ADV), 1 for proven IPA, 1 for concomitant proved
IPA and cytomegalovirus (CMV) reactivation, 1 for probable IPA and CMV
and BK virus (BKV) reactivations, 1 for proven IPA and multiple viral reac-
tivations, including ADV, CMV, and Epstein-Barr virus (EBV), 2 for CMV
reactivation, 1 for CMV and EBV reactivations, and 1 for CMV, EBV, ADV, and
BKV reactivations. The other 21 patients (IC-B group) had SD aGVHD and
cyclosporin A (CsA)erelated renal insufﬁciency in only 1 patient; SD aGVHD
and concomitant infections in the remaining 20 patients: CMV reactivations,
2; CMV and EBV reactivations, 4; CMV and BKV reactivations, 2; CMV, ADV,
and BKV reactivations, 1; EBV reactivations, 4; EBV and ADV reactivations, 1;
EBV reactivations and probable aspergillosis, 1; hepatitis B virus, 1; hepatitis
B virus and EBV reactivations, 1; CMV, EBV, and BKV reactivations, 1; ADV,
human herpesvirus-6, BKV, and coronavirus, 1; hepatitis C virus, CMV, and
proven IPA, n ¼ 1.
In our practice, surveillance for viral and fungal infections in blood is
routinely performed during the ﬁrst 100 days after HSCT in all patients and
includes EBV-DNA, CMV-DNA, ADV-DNA, human herpesvirus-6 DNA, BKV-
DNA, JC-DNA, and galactomannan antigen search. This schedule is per-
formed once each week in allo-HSCT recipients from HLA-identical sibling
and twice each week in allo-HSCT recipients from unrelated or hap-
loidentical donors. Monitoring viral infections in urine comprises CMV-DNA,
BKV-DNA, JCV-DNA in a weekly search. Blood, urine, and stool cultures;
nasal and throat swabs; and nasopharyngeal aspirates were weekly per-
formed. Search for other viruses or microbiological agents was performed
upon clinical symptoms. Viral reactivations were detected by PCR positivity
for EBV-DNA (cut-off: 1000 copies/mL), CMV-DNA (cut-off: 1000 copies/
mL), and ADV-DNA in qualitative test. Clinical systemic fungal infections
were deﬁned proved or probable according to European Organization for
Research and Treatment of Cancer criteria [21]. The cut-off for the gal-
actomannan index was set at .5 (Enzyme Immuno Assay (E.I.A.) method).
The algorithm for aGVHD treatment used in our center is shown in
Figure 1.
GVHD Prophylaxis
CsA was administered for 6 and 12 months in children who received
HSCT from an HLA-identical sibling or unrelated donor, respectively. In
unrelated HSCT, short-term methotrexate and rabbit antithymocyte glob-
ulin (ATG) were given. In unrelated cord blood HSCT, prophylaxis included
CsA and ATG. In haploidentical setting, ex vivo elimination of ab T cells and
CD19 B cells was done and ATG was administered before the cells were
infused; no other IS therapy was given after HSCT.
Informed consent was obtained from patients’ parents, as well as from
the patients themselves when possible, and the use of ECP was approved by
the ethical committee of the Hospital of Padova.
aGVHD Evaluation
The clinical organ involvement was graded and then combined to obtain
an overall grade, according to Glucksberg criteria for aGVHD [22]. Histo-
logical conﬁrmation was obtained whenever clinically indicated to conﬁrm
GVHD diagnosis.
Eligibility Criteria for ECP
Eligibility criteria for ECP treatment were as follows: children with SR
aGVHD (n ¼ 21); children with SD aGVHD (n ¼ 21); patients with aGVHD in
whom IS therapy was contraindicated or who required a rapid decrease of IS
therapy for increasing EBV viral load, CMV reactivation in 2 subsequent
samples, systemic fungal infections, intolerable side effects (n ¼ 30). All
children must present in complete hematological remission and full donor
chimerism; white blood cell (WBC) count > 1  109/L, and no concomitant
treatment with either ATG or monoclonal antibodies.
ECP Procedure and Technical Elements
ECP was performed using 2 different techniques: “in-line” treatment
(UVAR Photopheresis Instrument, Therakos, Exton, PA) was used in 19 of 72
patients and the “off-line” technique (Cobe Spectra, BCT Terumo, Lakewood,
CO) was used in 53 of 72 children. Technical descriptions have already been
published [19]. The “off-line” techniquewas introduced in 2003 to treat low-
weight children.
For patients weighing less than 15 kg, priming of the leukapheresis
circuit with irradiated and leuko-reduced red blood cells (regardless of
baseline hemoglobin level) was performed, as recommended in the Italian
Society of Haemapheresis and Cell Manipulation-Italian Group of Bone
Marrow Transplantation indications [19,23]. Pre-ECP hemoglobin levels
were maintained between 10 g/dL and 12 g/dL. The cell product was treated
with 8-MOP and diluted to a ﬁnal concentration of 20 mg/100 mL to 34 mg/
100 mL, according to speciﬁc procedures (in-line technique, 34 mg/100 mL;
off-line technique, 20 mg/100 mL).
Table 1
Clinical Characteristics of Patients Treated with ECP
Characteristic No. Patients Group by Reason for ECP
SR SD IC-A IC-B
72 21 21 9 21
Sex (M/F) 44/28 12/9 14/7 7/2 11/10
Disease
ALL 37 8 13 6 10
AML 16 9 3 0 4
MDS/AML secondary 6 1 2 1 2
CML 4 1 2 0 1
NHL 4 2 1 0 1
Others 5 0 0 2 3
Disease status at HSCT
CR1/CR2/CR3/other 26/30/3/13 12/6/1/2 6/11/0/4 2/2/2/3 6/11/0/4
Source of HSC
URD 54 17 11 7 19
BM; PBSC; CB 40; 8; 6 13; 1; 3 8; 2; 1 6; 1; 0 13; 4; 2
HLA identical sibling 15 3 9 1 2
BM; CB 14; 1 3; 0 8; 1 1; 0 2; 0
HLA-identical familiar donor 1 1 0 0 0
Haplo, TCRabCD19 depleted 2 0 1 1 0
Donor
Age, median (range), yr 28 (1-54) 28 (16-49) 27 (2-54) 27 (1-40) 27 (10-44)
Match/mismatched* 41/31 12/9 13/8 4/5 12/9
Sex mismatched 25/72 6/21 7/21 3/9 9/21
Female donor/male recipient 10/72 2/21 3/21 2/9 3/21
Conditioning regimen
Myeloablative: yes/no 70/2 21/0 21/0 8/1 20/1
TBI: yes/no 44/28 13/8 14/7 5/4 13/8
aGVHD: overall clinical grade at start of ECP
Grade I; II; III; IV 8; 29; 17; 18 0; 4; 6; 11 2; 9; 6; 4 3; 5; 1; 0 3; 11; 4; 3
aGVHD: organ involvement and grade at start of ECP
Skin 64 19 20 6 19
Grade I; II; III; IV 10; 21; 20; 13 2; 3; 8; 6 3; 8; 5; 4 2; 4; 0; 0 3; 6; 7; 3
Gut 55 18 17 6 14
Grade I; II; III; IV 27; 18; 2; 8 4; 5; 1; 8 9; 8; 0; 0 5; 0; 1; 0 9; 5; 0; 0
Liver 12 7 2 1 2
Grade I; II; III; IV 5; 4; 3; 0 1; 3; 3; 0 2; 0; 0; 0 1; 0; 0; 0 1; 1; 0; 0
Therapies before ECP
CsA (no steroid) 9 0 0 9 0
Steroids (þ others) 63 21 21 0 21
Age at ECP, median (range), yr 8.3 (.9-20.3) 7.9 (1.5-17.9) 8.3 (.9-20.3) 8.3 (1.8-17.1) 7.9 (1.6-18.3)
Body weight at ECP, median (range), kg 25 (7-98) 25 (9.6-85) 25 (7-98) 24 (13-38) 25 (10-52)
Interval HSCT to aGVHD, median (range), d 16 (6-64) 15 (6-32) 16 (8; 41) 17 (14-64) 16 (12-50)
Interval aGVHD to ECP, median (range), d 22 (4-81) 24 (4-63) 22 (14-81) 18 (5-29) 22 (5-56)
M indicates male; F, female; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; CML, chronic myeloid
leukemia; NHL, non-Hodgkin lymphoma; HSC, hematopoietic stem cell; URD, unrelated donor; BM, bone marrow; PBSC, peripheral blood stem cell; CB, cord
blood; Haplo, haploidentical parental donor; TBI, total body irradiation.
IC-A group is those with infectious complications and no steroid before ECP; the IC-B group is those with infectious complications and steroid before ECP.
* HLA match considered 6/6.
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In all patients, a 7 to 9 French Hickman double-lumen central catheter
was systematically used for the procedure. To provide adequate ﬂow rates,
ie, 1 to 2 mL/kg/minute, anticoagulationwith urokinase 10,000 U for 2 hours
as lock-therapy was performed on the day of the procedure.
Product’s characteristics (“off-line” technique)
The leukapheresis product contained a median of WBC of 19.4  103/uL
(range, 10.7 to 70.1  103), a median of mononuclear cells (MNC) of 80.5%
(range, 50% to 90%). The median number of WBC reinfused to the patients
was 2970106 (range,1150 to 10,420106), whereas themedian number of
MNC reinfused to the patients was 2794106 (range, 782.3 to 9805.4106).
Treatment protocol
Patients were treated with ECP twice each week for the ﬁrst month,
every 2 weeks during the second and third months, and then monthly for at
least 3 more months, for a total of 22 procedures. Progressive tapering
and discontinuation of ECP were decided upon evaluation of individual
response. Any concomitant IS therapy was initially maintained, then
modiﬁed or discontinued according to the clinical response.Response Criteria to ECP
Criteria for deﬁning response to ECP were previously reported [20]. All
patients enrolled for ECP before day þ100 were included in this group andresponse to ECP was evaluated at day þ28, day þ56, and at the end of ECP
treatment.
Complete response (CR) was deﬁned as the resolution of all signs of
aGVHD and partial response (PR) as at least a 50% improvement in the clinical
signs. In the latter case, given the complexity of assessing response, we
deﬁned PR for each organ as follows: for the skin, at least a 50% reduction in
the body surface area affected; for the GI tract and liver a 50% reduction in
the volume of diarrhea or value of bilirubin.
Any worsening of organ involvement, as well as the appearance of new
signs or symptoms of GVHD, was deﬁned as progressive disease (PD). Patients
with stable or PD were considered NR.aGVHD
Seventy-two consecutive patients with aGVHD received ECP at amedian
time of 46 days (range, 13 to 91) after HSCT and 22 days (range, 4 to 81) from
the diagnosis of aGVHD. Sixty-four patients had skin involvement (grade IV,
n ¼ 13; grade III, n ¼ 20; grade II, n ¼ 21; grade I, n ¼ 10). Fifty-ﬁve patients
had gastrointestinal (GI) aGVHD (grade IV, n ¼ 8; grade III, n ¼ 2; grade II,
n ¼ 18; grade I, n ¼ 27). Twelve patients had liver involvement (grade III,
n ¼ 3; grade II, n ¼ 4; grade I, n ¼ 5). Regarding the number of organs
involved: in 17 patients skin was affected and 7 presented GI involvement,
whereas 36 patients had combined skin and GI aGVHD, 1 patient had
combined GI and liver aGVHD, and 11 patients had combined skin, GI, and
liver aGVHD.
Diagnosis of aGVHD
No contraindications to steroid therapy
- Optimize CsA therapy
- Methyprednisolone 2 mg/kg
- Program ECP
Contraindications to steroid therapy
ECP
ECP
Second line treatment: 
Mycophenolate mofetil, FK, Rapamycin
Second line treatment: 
Mycophenolate mofetil, FK, Rapamycin
No responders to steroid 
and/or ECP 
Critic situation, not immediately available ECP, 
no response to steroid
ECP
ECP available
Third line treatment:
Mesenchymal Stem Cells, Methotrexate
Figure 1. Algorithm for aGVHD treatment used in our center.
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grade II, n ¼ 29; grade III, n ¼ 17; and grade IV, n ¼ 18; details of different
grades in the patients’ subgroups can be found in Table 1. The median
duration of treatment was 4months (range,1.1 to 10.2) for amedian number
of 18 procedures (range, 8 to 90). Forty-one out of 72 patients stopped ECP
early because of CR to ECP (20 patients), NR (8 patients), relapse of primary
disease (6 patients), clinical contraindications (such as sepsis in 6 patients),
and anaphylaxis (1 patient).
Clinical evaluation of the patients was conducted at every ECP proce-
dure. Sixty-three of 72 patients with aGVHD grades I to IV received 2 mg/kg/
day of MP as ﬁrst-line therapy. The median dose of steroid at the beginning
of ECP was 2 mg/kg/day. In detail, the IS therapies before ECP were CsA,
n ¼ 9; CsA plus steroid (2 mg/kg), n ¼ 42; tacrolimus plus steroid (2 mg/kg),
n ¼ 12; and CsA or tacrolimus plus MMF plus steroid, n¼ 9. ECP was used as
ﬁrst-line therapy in 8 of 72 patients, as second line therapy in 43 of 72 pa-
tients (among them, 1 haploidentical HSCT was treated only with CsA), as
third-line in 15 of 72 patients, and in 6 of 72 patients as fourth-line therapy.
Statistical Analysis
Patients’ characteristics were compared using the chi-squared or
Fisher’s exact test (as appropriate) in case of discrete variables, or the Mann-
Whitney test in case of continuous variables. TRM was calculated from the
date of HSCT to dayþ180 and to the last follow-up, considering as event any
nonrelapse cause of death. OS was calculated from the date of HSCT to the
date of death from any cause, or to the last follow-up. PFS was calculated
from the date of HSCT to the date of relapse of underlying primary disease or
death for any cause or to the last follow-up. TTPwas calculated from the date
of HSCT to the date of relapse of primary disease or to the last follow up.
Cumulative incidences (CI) of relapse of underlying disease were estimated
in the competing risk model, considering death from any cause or cGVHD as
the competing events. Survival analysis was performed using Kaplan-Meier
method with 95% conﬁdence interval. Standard error (SE) for each survival
and incidence rate is given. Differences between groups were compared
using the log-rank test and the Gray’s test. All reported P values were
2-sided, and statistical signiﬁcance was set at a ¼ .05 (SAS Institute, Cary,
NC; release 8.2) [24].RESULTS
Clinical Response to ECP
Response to ECP treatment, evaluated according to the
overall grading of aGVHD and to the organ involvement at
day þ28, day þ56, and at the end of ECP, is summarized in
Table 2.
At the end of treatment with ECP, 52 of 72 (72%) patients
had a CR, 8 of 72 (11%) had a PR, and 12 of 72 (17%) were NR.
Among the 52 patients showing a CR, 7 patients had aGVHD
grade I, 22 patients had grade II, 12 had grade III, and 11 had
grade IV. In particular, the CR rate for patients with aGVHD
grades I and II and grades III and IV were 78% and 66%,
respectively (P ¼ .70), whereas the PR rate for patients with
aGVHD grades I and II and grades II to IV were 5% and 17%,
respectively (P ¼ .80). No signiﬁcant statistical difference in
CR rate was observed according to the subgroups analyzed
(SR, 67%; SD, 81%; IC groups, 70%) (P ¼ .91).
At ECP discontinuation, CR of aGVHD manifestations of
skin, gut, and liver was observed in 78%, 76%, and 84%
of patients, respectively. Maximal response to ECP was
observed after 8 weeks of treatment (16 procedures).
As a result of ECP, at the end of treatment, it was possible
to discontinue IS therapy in 12 patients (17%) and reduce it in
44 patients (61%), of them 32 who received allo-HSCT from
an unrelated donor. Regarding the steroid tapering, in 63
patients treated with 2 mg/kg/day before ECP, the steroid
dose was reduced by 80% after 1 month of ECP treatment,
84% after 2months, and 88% after 3months of ECP treatment.
The median Lansky/Karnofsky performance score improved
from 70% before ECP to 100% after completing the treatment.
Table 2
Outcomes of Patients Treated with ECP according to Overall Grading of aGVHD and Organ Involvement
No. of Patients At Day þ28 At Day þ56 Stop ECP
CR PR NR CR PR NR CR PR NR
Overall grade
Grade I 8 6 0 2 7 0 1 7 0 1
Grade II 29 6 8 15 19 5 5 22 2 5
Grade III 17 5 8 4 9 4 4 12 2 3
Grade IV 18 4 12 2 11 5 2 11 4 3
Total (%) 72 21 (29%) 28 (39%) 23 (32%) 46 (64%) 14 (19%) 12 (17%) 52 (72%) 8 (11%) 12 (17%)
Organ involvement
Skin
Grade I 10 5 0 5 7 0 3 9 0 1
Grade II 21 8 8 5 16 4 1 17 2 2
Grade III 20 10 10 0 14 6 0 16 4 0
Grade IV 13 3 9 1 8 3 2 8 2 3
Total (%) 64 (100%) 26 (41%) 21 (42%) 11 (17%) 45 (70%) 13 (20%) 6 (10%) 50 (78%) 8 (13%) 6 (9%)
Gut
Grade I 27 15 0 12 22 0 5 23 0 4
Grade II 18 10 4 4 12 2 4 14 1 3
Grade III 2 1 0 1 1 0 1 1 0 1
Grade IV 8 3 4 1 4 3 1 4 4 0
Total (%) 55 (100%) 29 (53%) 8 (14%) 18 (33%) 39 (71%) 5 (9%) 11 (20%) 42 (76%) 5 (9%) 8 (15%)
Liver
Grade I 5 4 0 1 5 0 0 5 0 0
Grade II 4 2 1 1 3 0 1 3 0 1
Grade III 3 0 3 0 2 1 0 2 1 0
Grade IV 0 0 0 0 0 0 0 0 0 0
Total (%) 12 6 (50%) 4 (33%) 2 (17%) 10 (84%) 1 (8%) 1 (8%) 10 (84%) 1 (8%) 1 (8%)
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to ECP and the major clinical risk factors affecting aGVHD
(Table 3).
cGVHD
Twenty-three of 72 patients (32%) presented clinic man-
ifestations of cGVHD (Table 4). In detail, 19 patients (26%) had
progressive cGVHD (11 NR and 8 PR to ECP) and 4 patients
(5%) had quiescent cGVHD onset after a median of 6 months
(range, 5 days to 16 months) from the end of ECP. Overall
grading of cGVHD, based on the National Institutes of Health
Consensus [25], was mild for 6 patients, moderate for 10
patients, and severe for 7 patients.
Among the patients with progressive cGVHD, ECP was
used with other IS therapies in 4 of 19 patients, obtaining CRTable 3
Major Risk Factors of aGVHD and Response to ECP
Risk Factors P Value
Malignant disease (yes/no) 1.00
Median age of patient at HSCT (8.3 years) 1.00
Myeloablative conditioning regimen (yes/no) .48
TBI (yes/no) .67
Stem cell source: BM versus PBSC versus CB .84
Type of HSCT: URD versus HLA-identical Sibling 1.00
Donor gender: sex mismatch versus matched .56
Donor gender: F donor/M recipient versus others .45
Median age of donor: 28 yr .56
HLA: match versus mismatched .86
Hematopoietic stem cells infused* 1.00
Neutrophils engraftment (d þ15) 1.00
CMV reactivation (yes/no) .95
ECP technique (in-line/off-line) .73
Median interval of ECP’s beginning from onset
of aGVHD (day þ22)
.50
Median number of WBC infused (2970  106) .72
Median number of MNC infused (2794  106) .55
* BM: > 3  108 TNC/kg; PBSC: 5 to 10  106 CD34þ/kg; CB >3  107
TNC/kg.in only 1 of them. Overall, 10 of 19 patients were alive at the
last follow-up: 9 of 10 had no cGVHD and discontinued IS
therapy, whereas only 1 patient presenting with cGVHD was
still in treatment.
All the patients with quiescent cGVHD were alive at the
last follow-up: 2 patients were free from cGVHD andwithout
IS therapy and the other 2 patients had cGVHD and were still
on treatment with IS therapy plus ECP.
No association was found between responders and NR to
ECP and the onset of quiescent cGVHD.
Survival and Immunosuppression
At dayþ180, the overall TRMwas 4% (SE, 1%). TRMwas 3%
(SE, 2%) and 20% (SE, 13%) for responders and NR to ECP,
respectively (P < .0001). At last follow-up, the overall TRM
was 11% (SE, 4%), whereas TRM stratiﬁed between re-
sponders and NR was 3% (SE, 2%) and 58% (SE, 20%),
respectively (P < .0001) (Figure 2A,B).
The 5-year OS was 71% (SE, 5%) with a statistically sig-
niﬁcant difference between responders and NR (78%; SE, 5%
versus 30%; SE, 14%, respectively; P ¼ .0004) (Figure 3A,B).
The 5-year PFS of primary disease for all the group was 72%
(SE, 5%), with a signiﬁcant difference (P ¼ .0007) between
responders (79%; SE, 5%) and NR (30%; SE, 14%) (Figure 4A,B).
Overall, the 5-year TTP of primary disease was 81% (SE, 5%),
without any signiﬁcant difference between the 2 groups
(responders: 82%; SE 5% versus NR: 78%; SE, 14%; P ¼ .65)
(Figure 5A,B).
We compared patients’ survival rates on ECP treatment
used as ﬁrst, second, or third/fourth-line therapy. No differ-
ence was observed at 5-years between responders and NR in
term of OS (P ¼ .56), PFS (P ¼ .55), and TTP (P ¼ .62).
The overall 5-year CI of relapse of the underlying disease
was 20% (SE, 5%); in particular, it was 21% (SE, 6%) and 20% (SE,
9%) for responders and NR to ECP, respectively (Figure 6A,B).
Overall, at the last follow-up (median time from HSCT of
5 years; range, .18 to 17.6 years), 51 patients were alive (71%);
Table 4
Follow-Up of Patients with cGVHD
Patient Group aGVHD
Grade
No. of
ECP
ECP
Line
Response
to ECP
Status at
Last FU
Last
FU, yr*
Cause of Death cGVHD
Grade
IS for cGVHD cGVHD
at Last FU
IS at
Last FU
Progressive
cGVHD
1 SR 4 12 2 PR Alive 11.2 Moderate FK þ steroid þ ECP No No
2 SR 4 10 2 PR Alive 11.2 Moderate FK No No
3 SR 4 26 3 NR Alive 27.3 Severe High-dose steroid þ
MMF þ FK
steroid þ imatinid
FK þ steroid
Yes Yes
4 SR 3 18 2 PR Dead 1.3 Relapse Moderate CSA þ steroid Yes No
5 SR 4 16 2 PR Alive 14.6 Moderate CSA þ MMF þ steroid No No
6 SR 4 90 3 NR Dead 2.6 GVHD (MOF) Severe FK þ MMF þ steroid
FK þ steroid þ ECP
FK þ MMF þ rituximab þ
ECP
FK þ steroid þ imatinib
Yes Yes
7 SD 3 20 2 NR Dead .03 Infection Moderate MMF þ steroid Yes Yes
8 SD 2 28 2 NR Alive 7.8 Mild FK þ MMF þ steroid No No
9 SD 4 12 3 PR Alive 7.6 Moderate FK þ steroid No No
10 SD 2 14 4 NR Dead .3 Infection Severe FK þ MMF þ steroid
CSA þ steroid þ ECP
Yes Yes
11 IC(A) 3 18 1 NR Alive 3.2 Severe FK þ steroid, Rapamycin þ
steroid
No No
12 IC(B) 2 16 3 NR Dead .5 Relapse Mild FK Yes No
13 IC(B) 2 20 3 PR Dead .2 Relapse Mild FK þ steroid Yes No
14 IC(B) 2 28 2 PR Alive 9.1 Moderate FK þ MMF No No
15 IC(B) 3 14 2 PR Alive 8.4 Moderate FK þ steroid No No
16 IC(B) 2 6 2 NR Dead .3 Encephalopathy Moderate MMF No No
17 IC(B) 2 8 2 NR Dead .5 Relapse Moderate FK þ steroid No No
18 IC(B) 1 15 2 NR Alive 2.5 Severe FK þ MMF þ steroid
Mesenchymal stem cells
Imatinib þ FK þ seroid
FK þ steroid
No No
19 IC(B) 4 22 2 NR Dead .7 GVHD (MOF) Severe FK þ steroid þ imatinib,
FK þ steroid þ Imatinib þ
PUVA
FK þ steroid þ CPM þ
MTX þ imatinib þ ECP
Yes Yes
Quiescent
cGVHD
20 SR 3 30 4 CR Alive 3.7 Severe FK þ MMF þ steroid þ
ECP
Rapamycin
PUVA þ Rituximab
FK þ MMF þ steroid þ
PUVA
FK þ imatinib þ PUVA
Yes Yes
21 IC(A) 2 22 1 CR Alive 9.2 Mild FK þ steroid
MMF
No No
22 IC(B) 2 22 2 CR Alive 7.2 Mild CSA No No
23 SD 4 11 2 CR Alive .4 Mild CSA þ steroid þ ECP Yes Yes
FU indicates follow-up; FK, tacrolimus; MOF, multi-organ failure; PUVA, psoralen combined with ultraviolet A; CPM, cyclophosphamide; MTX, methotrexate.
IC(A): infection complications, no steroid before ECP; IC(B): infection complications, steroid-dependent.
* Median time from end of ECP to last follow-up.
Figure 2. (A) TRM for all patients. (B) TRM for responders and NR to ECP.
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Figure 3. (A) Five-year OS for all patients treated with ECP. (B) Five-year OS for responders and NR to ECP.
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therapy. Twenty-one patients (29%) died: 14 from relapse of
primary disease and 7 from NRM. Among this last group, 1
patient with aGVHD died at day þ65 from HSCT because
of sepsis; 5 patients with cGVHD died from CMV pneumonia
(1 case), acute hepatitis from HCV infection (1 case), en-
cephalopathy (1 case), andmultiorgan failure (2 cases); and 1
patient died from CMV pneumonia at day þ135 from HSCT,
without evidence of cGVHD.
Complications
Side effects observed during ECP were generally mild and
more frequent in low-weight children. ECP caused mild hy-
potension in 10 patients associated with abdominal pain in
all cases (16 episodes out of 1382 apheresis sessions). These
adverse effects did warrant suspending the procedure. A
transient reduction in hemoglobin, platelet, and/or WBC
count during the ECP treatment, likely independent from the
post-transplantation course and putatively ECP-related, was
observed in 26, 20, and 25 patients, respectively. One patient
with grade IV aGVHD on high-dose steroid therapy (5 mg/kg/
day) experienced acute GI bleeding after the second course of
ECP: GI endoscopy showed multiple ulcers in the stomach. A
girl with pre-existing cardiac impairment showed acute
heart failure for ﬂuid overload after the procedure that
quickly responded to adequate therapy. One girl, after 10 ECP
procedures, had anaphylaxis (cough, vomiting, abdominal
pain, hypotension, and palpebral edema) a fewminutes after
the end of 8-MOP irradiated bag infusion. She responded toFigure 4. (A) Overall 5-PFS of primary disease. (B) Five-yearantihistamine and steroid therapy, but ECP treatment was
then stopped.
DISCUSSION
The aim of this retrospective study was to analyze the role
of ECP for the treatment of aGVHD. The efﬁcacy of ECP is well
established for treatment of cGVHD [26,27], whereas in
aGVHD, no prospective randomized studies have been pub-
lished. However, the use of ECP is suggested as second-line
therapy, together with mammalian target of rapamycin in-
hibitors, MMF, IL-2 receptor antibodies, and anti-TNF anti-
bodies [3]. The largest phase 2 prospective study exploring
feasibility and efﬁcacy of ECP in treatment of aGVHD in
adults, involving 59 patients, was performed by Greinix et al.
[14] and reported a CR rates of 82% for skin and 61% for liver
and GI aGVHD. So far, data on 207 pediatric patients treated
with ECP for aGVHD have been reported, showing an overall
CR rate ranging from 32% to 73% and a survival rate ranging
from 44% to 85% [18,20,28-34].
To date, our is the largest pediatric case series treated in a
single center. In our sample size, we found a higher overall
response rate to ECP compared with a multicenter retro-
spective study of the Italian Association for Pediatric He-
matology/Oncology (AIEOP) (72% versus 54%) [18]. We
attempted to determine the factors that may have inﬂuenced
our observed higher response. In the last 15 years, many
changes have been introduced in HSCT, such as high-
resolution HLA typing, new agents in the conditioning
regimen, more use of ATG, monoclonal antibodies, and newPFS of primary disease according to response to ECP.
Figure 5. (A) Overall 5-year TTP of primary disease. (B) Five-year TTP of primary disease according to response to ECP.
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cation may have inﬂuenced the outcome. We could also
hypothesize that speciﬁc expertise in pediatric HSCT and
earlier treatment with ECP (22 days in our series versus
30 days in AEIOP study) may have improved the overall
outcome. Further studies are needed to address this topic.
No association was found between responders and NR
setting to ECP and major risk factors for aGVHD. In addition,
in our series, no difference was found according to the grade
of GVHD (grade I and II, 78%; versus grade III and IV, 66%; P¼
.70) and to the subgroups of patients analyzed (SR, 67%; SD,
81%; IC, 70%; P ¼ .91). Our results showed better response
rate than those reported in literature for advanced stages of
disease, where higher grades and poorer response to IS
therapy correlate with a worst outcome [6]. Nevertheless,
higher CR rates were observed in grade II GVHD, suggesting
that an early start of ECP sessionsmay be beneﬁcial, even if in
our study the timing to start ECP (<22 versus > 22 days) did
not inﬂuence the response. In our group, ECP seemed to be
effective in all the involved organs. As previously reported,
our results support that ECP is a steroid-sparing treatment;
in fact, the steroid dose was reduced by 80%, 84%, and 88%
after 1, 2, and 3 months, respectively from the onset of ECP.
We performed ECP as front-line therapy in 8 patients with
fungal infection and viral reactivation and aGVHD, with
complete response in 7 of them. To our knowledge, this is the
ﬁrst report of ECP as ﬁrst-line treatment. IS therapy was
either discontinued or reduced in 78% of responding pa-
tients. It is well known from the literature that IS therapyFigure 6. (A) Overall cumulative incidence of relapse of primary disease. (B) Cumuincreases the risk of infectious complications and relapse of
underlying disease after allo-HSCT [1,2,18,20,28,35].
In children, who may be particularly vulnerable to the
consequence of GVHD itself and prolonged treatment with IS
agents, the use of ECP is particularly appealing. The efﬁcacy
of ECP in controlling GVHD did not affect the preservation of
graft-versus-leukemia effect; in fact, the low incidence of
relapse of underlying disease was recorded by us and others
[17,18,20,28].
Many concerns has been raised related to the technical
aspects of apheresis in the pediatric setting. In children with
low body weight, the caregivers should carefully monitor
patients for signs and symptoms of hypovolemia. In our
experience, ECP was well tolerated, with few and mild
adverse effects, the most frequent of which were mild hy-
potension, abdominal pain, and headache. Curiously, these
symptoms were recorded more often during ECP compared
with other apheretic procedures [19,34]. The majority of side
effects were observed in the earliest period inwhich ECP was
performed in our center. All these observations support the
idea that there has been a learning process for the manage-
ment of technical elements and side effects. In our experi-
ence, ECP was feasible even in 15 very young children with
low body weight (<15 kg). Technically, we performed
priming of the circuit with irradiated and leukodepleted red
blood cells (regardless of baseline hemoglobin level). Some
authors recently reported that saline infusion or albumin
boluses may be an alternative priming approach in patients
with body weight ranging from 19 to 39 kg [36]. However, itlative incidence of relapse of primary disease for responders and NR to ECP.
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ferred to population weighting less than 15 kg. Currently
used ECP techniques include the “off-line” and the “in-line”
devices [19]. In our center, both techniques were used in
different time periods with no difference in response rate
observed. The number of WBC collected and MNC reinfused
did not affect clinical outcome. Notably, all patients under-
went the procedure with the bilumen central venous line
already in place (Hickman-Broviac Bard Access Systems, Salt
Lake City, UT, USA), which is different from the majority of
reports, in which a larger central venous line (for instance,
quinton) is placed. It would be interesting to extend our
experience to determine if urokinase anticoagulation allows
the proper ﬂow rate of pre-existing central venous line.
Further, because of the experience of the staff in completing
the procedure, no patient required sedation.
The CI of cGVHD in pediatric population ranged from 6%
to 65% according to the source of stem cells (HLA-identical
sibling cord blood versus matched unrelated donor periph-
eral blood) [37,38], whereas in the AIEOP experience, the CI
of cGVHDwas reported to be 27% [39]. In our small series, the
incidence of cGVHD was 32%. The majority of our children
presented progressive cGVHD (26%) and few had quiescent
cGVHD (5%). For this reason, it is hard to determine if pa-
tients previously treated with ECP for aGVHD could beneﬁt
from retreatment.
Our data are consistent with literature and the results
encourage us in exploiting this promising approach for
aGVHD. In conclusion, a standardized approach to ECP
treatment is needed for pediatric patients. From this
perspective, sharing single-center experience is of great
value in building experience; however, it is time to propose
randomized prospective trials.ACKNOWLEDGMENTS
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